Active, not recruiting.FMT combined with anti-PD-1 treatment induced changes in the gut microbiome composition and transformed the tumor microenvironment, effectively overcoming resistance to anti-PD-1 in a specific group of advanced melanoma patients. The gene discussed is PDCD1; the disease is melanoma.